Furthermore, Chen et al. has demonstrated that dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma cells via suppression of the activation of Akt [39]. This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.